Oxygen carriers as blood substitutes: Past, present, and future

Clinical Orthopaedics and Related Research

Volumn 357, Issue , 1998, Pages 89-100

  Goodnough, Lawrence T ^a   Scott, Mitchell G ^a   Monk, Terri G ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD SUBSTITUTE; FLUOROCARBON; HEMOGLOBIN;

ANEMIA; BLOOD TRANSFUSION; BLOOD VOLUME; CONFERENCE PAPER; FLUSHING; HEMODILUTION; HUMAN; MAJOR SURGERY; MALAISE; OXYGEN CONSUMPTION; OXYGEN SATURATION; OXYGEN TRANSPORT; PRIORITY JOURNAL; THROMBOCYTOPENIA;

EID: 0032422355     PISSN: 0009921X     EISSN: 15281132     Source Type: Journal    
DOI: 10.1097/00003086-199812000-00013     Document Type: Conference Paper

References (83)

1. Abassi Z, Kotob S, Pieruzzi F, et al: Effects of polymerization on the hypertensive action of diasprin cross-linked hemoglobin in rats. J Lab Clin Med 129:603-610, 1997.
2. Amberson WR, Flexner J, Steggerda FR, et al: On the use of Ringer-Locke solutions containing hemoglobin as a substitute for normal blood in mammals. J Cell Comp Physiol 5:359-382, 1934.
3. Amberson WR, Jennings JJ, Rhode CM: Clinical experience with hemoglobin-saline solutions. J Appl Physiol 1:469-489, 1949.
4. American College of Physicians: Practice strategies for elective red blood cell transfusions. Ann Intern Med 116:403-406, 1992.
5. Arnone A: X-ray diffraction study of binding of 2,3-diphosphoglycerate to human deoxyhemoglobin. Nature 23:146-149, 1972.
6. Baron JF, Berridge JC, Brichant JF, et al: The use of diaspirin crosslinked hemoglobin as an alternative to blood transfusion in cardiac surgery patients following cardiopulmonary bypass. Anesthesiology 87:A217, 1997. Abstract.
7. Bowersox JC, Hess JR: Trauma and military applications of blood substitutes. Artif Cells Blood Substit Immobil Biotechnol 22:145-157, 1994.
8. Brandt JL, Frank NR, Lichtman H: The effects of hemoglobin solutions on renal function in man. Blood 6:1152-1158, 1951.
9. Bunn HF: The use of hemoglobin as a "blood substitute". Am J Hematol 42:112-117, 1993.
10. Bunn HF, Esham WT, Bull RW: The renal handling of hemoglobin.I. Glomerular filtration. J Exp Med 129:909-923, 1969.
11. Chatterjee R, Welty EV, Walder RY et al: Isolation and characterization of a new hemoglobin derivative cross-linked between the α chains (lysine 99α1-lysine 99 α2). J Biol Chem 261:9929-9937, 1986.
12. Clark LC, Gollan F: Survival of mammals breathing liquids equilibrated with oxygen at atmospheric pressure. Science 152:1755-1756, 1966.
13. Cone A: The use of colloids in clinical practice. Br J Hospital Med 54:155-159, 1995.
14. Dietz NM, Joyner MJ, Warner MA: Blood substitutes: Fluids, drugs or miracle solutions. Anesth Analg 82:390-405, 1996.
15. Estep TN, Gonder J, Bornstein I, Aono F: Immunogenicity of diaspirin cross-linked human hemoglobin solutions. Artif Cells Blood Substit Immobil Biotechnol 20:603-609, 1992.
16. Faithful NS: Mechanisms and efficacy of fluorochemical oxygen transport and delivery. Artif Cells Blood Substit Immobil Biotechnol 22:181-197, 1994.
17. Feola M, Gonzales H, Canizaro PC, Bingham D, Periman P: Development of a bovine stroma-free hemoglobin solution as a "blood substitute". Surg Gynecol Obstet 157:399-408, 1983.
18. Feola M, Simoni J, Angelillo R, et al: Clinical trial of a hemoglobin-based "blood substitute" in patients with sickle cell anemia. Surg Gynecol Obstet 174:379-386, 1992.
19. Flaim SF, Hazard DR, Hogan J, Peters RM: Characterization and mechanism of side-effects of Oxygent HT in swine. Artif Cells Blood Substit Immobil Biotechnol 19:383-385, 1991.
20. Fox JL: Assessing blood substitutes: Biotechnology 12:231-232, 1994.
21. Franticelli C, Bucci E, Orth C: Solvent regulation of oxygen affinity in hemoglobin. J Biol Chem 259:10841-10844, 1984.
22. Goodin TH, Grossbard EB, Kaufman RJ, et al: A perfluorochemical emulsion for prehospital resuscitation of experimental hemmorhagic shock: A prospective, randomized control study. Crit Care Med 22:680-689, 1994.
23. Goodnough LT, Bodner MS, Martin JW: Blood transfusion and blood conservation: Cost and utilization issues. Am J Med Qual 9:172-183, 1994.
24. Goodnough LT, Monk TG, Andriole GL: Erythropoietin therapy. New Engl J Med 336:933-938, 1997.
25. Goodnough LT, Monk TG, Brecher ME: Autologous blood procurement in the surgical setting: Lessons to be learned in the last 10 years. Vox Sang 71:133-141, 1996.
26. Goodnough LT, Monk TG, Brecher ME: Acute normovolemic hemodilution in surgery. Hematology 2:413-420, 1997.
27. Goodnough LT, Shafron D, Marcus RE: Impact of preoperative autologous blood donation in orthopedic surgical practice. Vox Sang 59:65-69, 1990.
28. Gould SA, Moore EF, Moore FA, et al: Clinical utility of human polymerized hemoglobin as a blood substitute after acute trauma and urgent surgery. J Trauma 43:325-332, 1997.
29. Gould SA, Rosen AL, Sehgal LR, et al: Fluosol-DA as a red cell substitute in acute anemia. N Engl J Med 314:1653-1656, 1986.
30. 2 carrier. Ann Surg 311:394-398, 1990.
31. Griffiths E, Cortes A, Gilbert N, et al: Haemoglobin-based blood substitutes and sepsis. Lancet 345: 158-160, 1995.
32. 2 dissociates curves of blood Fluosol-DA 20% mixtures. Adv Exp Med Biol 191:453-461, 1985.
33. Hankeln K, Radel C, Beez M, Laniewski P, Bohmert F: Comparison of hydroxyethyl starch and lactated Ringers' in hemodynamics and oxygen transport of critically ill patients in prospective crossover studies. Crit Care Med 17:133-135, 1989.
34. Hess JR, MacDonald VW, Brinkley WW: Systemic and pulmonary hypertension after resucitation with cell-free hemoglobin. J Appl Physiol 74:1769-1778, 1993.
35. Hess JR, MacDonald VW, Gomez CS, Coppes V: Increased vascular resistance with hemoglobin-based oxygen carriers. Artif Cells Blood Substit Immunol Biotechnol 22:361-372, 1994.
36. Hirschl RB, Parent A, Tooley R, et al: Liquid ventilation improves pulmonary function, gas exchange and lung injury in a model of respiratory failure. Ann Surgery 221:79-88, 1995.
37. Holman WL, McGiffin DC, Viccate WV, Spruell RD, Pacifico AD: Use of current generation perfluorocarbon emulsions in cardiac surgery. Artif Cells Blood Substit Immunol Biotechnol 22:979-990, 1994.
38. Hughes GS, Francom SF, Antal EJ, et al: Hematologic effects of a novel homoglobin-based oxygen carrier in normal male and female subjects. J Lab Clin Med 126:444-451, 1995.
39. Hughes G, Jacob E, Francom S: A novel hemoglobin-based oxygen carrier accelerates erythropoiesis in surgical patients. Crit Care Med 24:A36, 1996. Abstract.
40. Hughes GS, Yancey EP, Albrecht R, et al: Hemoglobin-based oxygen carrier preserves submaximal exercise capacity in humans. Clin Pharmacol Ther 58:434-443, 1995.
41. Janeway CA, Travers P: The Induction and Detection of Immune Responses. Immunobiology. The Immune System in Health and Disease. New York, Garland Publishing Inc. 2-8, 1994.
42. Jones JA: Red blood cell substitutes: Current status. Br J Anaesth 74:697-703, 1995.
43. 2 delivery by perfluorocarbon emulsion during acute hemodilution. Artif Cells Blood Substit Immunol Biotechnol 22:1161-1167, 1994.
44. Kernis DM: Role of the perfluorocarbon Fluosol-DA in coronary angioplasty. Am J Med Sci 307:218-221, 1994.
45. Komiyama NH, Miyazaki G, Tame J, Nagai K: Transplanting a unique allosteric effect from crocodile into human hemoglobin. Nature 373:244-246, 1995.
46. Krieter H, Hagen G, Waschke KF, et al: Isovolemic hemodilution with a bovine hemoglobin based carrier: effects on hemodynamics and oxygen transport in comparison to a no oxygen carrying volume substitute in dogs. J Cardiothorac Vasc Anesth 11:3-9, 1997.
47. Kumar R: Recombinant hemoglobin as blood substitutes: A biotechnology perspective. Proc Soc Exp Biol Med 208:150-158, 1995.
48. Langermans JAM, Bleeker WK: Haemoglobin-based blood substitutes and infection. Lancet 345: 863-864, 1995.
49. Leach CL, Greenspan JS, Rubenstein SD, et al: Partial liquid ventilation with perflubron in premature infants with severe respiratory distress syndrome. N Engl J Med 335:761-767, 1996.
50. Lee R, Neya K, Suizzero TA, Vlahakes GJ: Limitations of the efficacy of hemoglobin-based oxygen-carrying solutions. J Appl Physiol 79:236-242, 1995.
51. Looker D, Abbott-Brown D, Cozart P, et al: A human recombinant haemoglobin designed for use as a "blood substitute". Nature 356:258-260, 1992.
52. Loscalzo J: Nitric oxide binding and the adverse effects of cell-free hemoglobins: What makes us different from earthworms. J Lab Clin Med 129:580-583, 1997.
53. Ma Z, Monk TG, Goodnough LT, et al: Effect of hemoglobin and perflubron-based oxygen carriers on common clinical laboratory tests. Clin Chem 43:1732-1737, 1997.
54. Monk TG, Goodnough LT, Birkmayer JD, Brecher ME, Catalona WJ: Acute normovolemic hemodilution is a cost-effective alternative to pre-operative autologous blood donation by patients undergoing radical retropubic prostatectomy. Transfusion 35:559-565, 1995.
55. Monk TG, Goodnough LT, Peruzzi WT, et al: A dose-escalation study to evaluate the kinetics and hemodynamic effects of hemoglobin-based oxygen carrier-201. Anesthesia 87:A214, 1997. Abstract.
56. National Institutes of Health Consensus Conference: Perioperative red cell transfusion. JAMA 260: 2700-2703, 1988.
57. Palmer RMJ, Ferrige AG, Moncoda S: Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 327:524-526, 1987.
58. Pruet TL, Rotstein OD, Wells CL, Sorenson JJ, Simmons RL: Mechanism of the adjuvant effect of hemoglobin in experimental peritonitis IX: The infection potentiating effect of hemoglobin in E. coli peritonitis is strain specific. Surgery 98:371-377, 1985.
59. Riess JG: Fluorocarbon-based in vivo oxygen transport and delivery systems. Vox Sang 61:225-239, 1991.
60. Rudolph AS: Biomaterial biotechnology using self-assembled lipid microstructures. J Cell Biochem 56:183-187, 1985.
61. Sanders KE, Ackers G, Sligor S: Engineering and design of blood substitutes. Curr Opin Struct Biol 6:534-540, 1996.
62. Savitsky JP, Doczi J, Black J, Arnold JD: A clinical safety trial of stroma-free hemoglobin. Clin Pharmacol Ther 23:73-80, 1978.
63. Sazama K: Reports of 355 transfusion-associated deaths: 1975 through 1985. Transfusion 30: 583-590, 1990.
64. Schreiber GB, Busch MP, Kleinman SH, Korelitz JJ: The risk of transfusion-transmitted viral infections. N Engl J Med 334:1685-1690, 1996.
65. Schultz SC, Grady B, Cole F, et al: A role for endothelin and nitric oxide in the pressor response to diaspirin cross-linked hemoglobin. J Lab Clin Med 122:301-308, 1993.
66. Service RF: Small spheres lead to big ideas (Research News). Science 267:327-329, 1995.
67. Sharma A, Martin MJ, Okabe JF, et al: An isologous porcine promoter permits high level expression of human hemoglobin in transgenic swine. Biotechnology 12:55-59, 1993.
68. Skolnick AA: As the blood supply gets safer, experts still call for ways to reduce the need for transfusion. JAMA 268:698-700, 1992.
69. Slanetz PJ, Lee R, Page R, et al: Hemoglobin blood substitutes in extended preoperative autologous blood donation: An experimental study. Surgery 115:246-254, 1994.
70. Smith DJ, Lane TA: Effect of a high concentration perfluorocarbon emulsion on platelet function. Artif Cells Blood Substit Immunol Biotechnol 20: 1045-1049, 1992.
71. Surgenor DM, Wallace EL, Hao SHS, Chapman RH: Collection and transfusion of blood and blood components in the United States, 1982-88. N Engl J Med 322:1646-1651, 1990.
72. Teicher BA, Holden SA, Ara G, Dupuis NP, Goff D: Restoration of tumor oxygenation after cytotoxic therapy by a perflubron emulsion/carbogen breathing. Cancer 1:43-48, 1995.
73. Tremper KK: Hemoglobin-based oxygen carriers: Problems and promise. J Cardiothorac Vasc Anest 11:1-2, 1997.
74. Tremper KK, Friedman AE, Levine EM, Lapin R, Camarillo D: The preoperative treatment of severely anemic patients with a perfluorochemical oxygen-transport fluid, 7luosol-DA. N Engl J Med 307: 277-283, 1982.
75. Vamvakas EC, Taswell HF: Epidemiology of blood transfusion. Transfusion 35:802-812, 1995.
76. Vitu-Loos L, Thomas C, Chavaudra N, Guichard M: Radiosensitivity, blood perfusion and tumor oxygenation after perflubron emulsion injection. Radiother Oncol 27:149-155, 1993.
77. Vlahakes GJ, Lee R, Jacobs EE, La Raias PJ, Austen WG: Hemodynamic effects and oxygen transport properties of a new "blood substitute" in a model of massive blood replacement. J Thorac Cardiovasc Surg 100:379-388, 1990.
78. Wahr JA, Anderson MM, Giacherio DA, et al: Effects of a blood salvaging device on blood containing a hemoglobin based oxygen carrier. HBOC-201. J Cardiothorac Vasc Anesth 11:10-12, 1997.
79. Wahr JA, Trouwborst A, Spence RK, et al: A pilot study of the effects of a Perflubron emulsion, AF0104, on mixed venous oxygen tension in anesthetized surgical patients. Anesth Analg 82: 103-107, 1996.
80. Wallace EL, Churchill WH, Surgenor DM, et al: Collection and transfusion of blood and blood components in the United States, 1992. Transfusion 33:139-144, 1993.
81. Winslow RM: Blood Substitutes In Nance EJ (ed). Blood Safety: Current Challenges. Bethesda, MD American Association Blood Banks 151-167, 1992.
82. Winslow RM: Blood substitutes, a moving target. Nat Med 1:1212-1215, 1995.
83. Zuck TF, Riess JG: Current status of injectable oxygen carriers. Crit Rev Clin Lab Sci 31:295-324, 1994.